DEA Hearing Preview: What Broader Rescheduling Could Mean
Jamie
Head Cultivator
The DEA has a major hearing on the calendar: June 29, 2026. That's when a federal administrative law judge will begin weighing whether cannabis — all of it, not just the medical stuff — should move from Schedule I to Schedule III under federal law.
If you buy flower at a Michigan dispensary and you're wondering whether any of this affects you, the short answer is: maybe, eventually, but not the way the headlines usually make it sound.
What Is the DEA's June 29 Hearing and Why Does It Matter? #
The June 29, 2026 DEA hearing is the next major step toward deciding whether all cannabis — including adult-use products — should be moved from Schedule I to Schedule III under federal law. It's an administrative legal process, not a vote, and it doesn't instantly change anything. But it's the clearest path the federal government has taken toward treating cannabis like a medicine rather than a hard drug.
Here's the basic setup. The Drug Enforcement Administration holds hearings before an administrative law judge when it wants to change how a substance is classified under the Controlled Substances Act. These hearings let businesses, advocacy groups, researchers, and the public submit testimony on both sides. The judge then makes a recommendation, and the DEA issues a final rule.
For cannabis, this process has been slow and messy for years. But the hearing that starts June 29 is described by the DOJ as an "expedited" process — meaning the government wants to move faster than the prior round of hearings, which dragged on and were ultimately terminated.
The stakes are real. If broader rescheduling goes through, it would be the single biggest shift in federal cannabis law in over 50 years.
| What the Hearing Addresses | Current Status |
|---|---|
| Broader rescheduling (all cannabis) | Hearing begins June 29, 2026 |
| State-licensed medical cannabis | Already Schedule III (since April 28, 2026) |
| FDA-approved cannabis products | Already Schedule III (since April 28, 2026) |
| Adult-use / recreational cannabis | Still Schedule I — pending hearing outcome |
What Already Changed: The April 28, 2026 Schedule III Order #
As of April 28, 2026, state-licensed medical cannabis and FDA-approved cannabis products are already Schedule III under federal law. This is done — it happened. The Federal Register published the DEA/DOJ order on April 28, 2026, and it took effect that same day.
What that means in practice: if you hold a Michigan medical marijuana card and buy at a licensed medical dispensary, the product you're buying is now technically covered by a Schedule III classification at the federal level. Same goes for products like Epidiolex (an FDA-approved CBD drug used for epilepsy).
What it does NOT mean: adult-use, recreational flower bought at your regular Michigan dispensary is still Schedule I. The April order drew a specific line — state-licensed medical use on one side, everything else on the other.
This is where a lot of people get confused. You'll see headlines like "cannabis is now Schedule III" and think the whole plant is reclassified. It's not. The Drug Policy Alliance's May 2026 explainer makes the split clear: the April order was a limited move, and the June 29 hearing is where the broader question gets decided.
The other thing that happened in April: the prior DEA hearing process — the one started under Biden in 2024 — was terminated. A new, faster process was put in place. That's the June 29 hearing.
Quick Timeline to April 28, 2026 #
- August 2023 — HHS recommends Schedule III to DEA
- May 2024 — DEA/DOJ publish proposed rule in Federal Register
- 2024–early 2026 — Hearing proceedings drag on, get challenged
- April 22, 2026 — Acting AG Todd Blanche issues partial Schedule III order
- April 28, 2026 — Order takes effect for medical cannabis and FDA products
- June 29, 2026 — New hearing begins on broader rescheduling
Schedule I vs. Schedule III: What These Labels Actually Mean #
Schedule I means the federal government officially treats a drug as having no accepted medical use and a high potential for abuse. Schedule III means the drug is recognized as having medical value with a moderate-to-low potential for dependence. Those are the DEA's own definitions.
Think of it like a rating system from the feds. The lower the schedule number, the more tightly controlled. Schedule I is the most restricted category — it's where heroin and LSD also sit, alongside cannabis. Schedule III includes things like anabolic steroids and ketamine.
Here's the thing: moving cannabis from Schedule I to Schedule III doesn't make it an over-the-counter product. It doesn't make it legal the way beer is legal. It still sits on a federal controlled-substances list. But it changes how the federal government treats the people and businesses working with it.
| Schedule I | Schedule III | |
|---|---|---|
| Accepted medical use? | No (officially) | Yes |
| Dependence potential | High (per federal rules) | Moderate to low |
| Can businesses deduct expenses? | No (blocked by 280E) | Yes |
| Research barriers | Very high | Significantly lower |
| Examples | Heroin, LSD, cannabis (for now) | Ketamine, anabolic steroids, Tylenol with codeine |
| Federal penalty level | Harshest | Less severe |
The label change matters mostly for businesses and researchers. For someone buying flower at a Michigan dispensary, the day-to-day experience at the counter doesn't automatically flip — but the business on the other side of that counter would get real financial relief.
What Broader Rescheduling Could Change for Consumers #
Broader rescheduling would most likely affect cannabis consumers indirectly — through lower business taxes, easier research, and slightly better banking access — rather than changing what you can buy or where. Don't expect a totally different experience at the dispensary counter. But don't dismiss it either.
Here's what could trickle down to everyday shoppers:
1. Possibly Lower Prices (Eventually) #
The biggest practical change from rescheduling is the death of a tax rule called Section 280E. Right now, cannabis businesses can't deduct normal operating expenses — things like rent, payroll, and utilities — because federal tax law blocks deductions for businesses trafficking in Schedule I or II drugs. That artificially inflates costs for every dispensary you walk into.
Under Schedule III, those deductions would be allowed again. Whether businesses pass savings on to you depends on competition and margins, but over time, healthier financials for the industry tend to help prices.
2. More and Better Research #
Right now, running a clinical study on cannabis is a federal headache. Schedule I status creates layers of DEA oversight that slow down scientists. Schedule III would ease those barriers significantly, as Michigan Medicine noted in its 2026 analysis. More research means better dosing guidance, better strain-effect data, and smarter products over time.
3. More Stable Dispensaries #
With easier access to banking and normal tax treatment, dispensaries are less likely to close suddenly or cut corners to survive. More stable businesses mean more consistent product quality and availability.
4. Potential Licensing Improvements #
Some of the friction in the Michigan market — particularly around getting licenses and attracting capital for equity operators — stems partly from federal illegality. Rescheduling wouldn't fix everything, but it would reduce one layer of that friction.
What Rescheduling Does NOT Do #
Rescheduling cannabis from Schedule I to Schedule III does not make it federally legal in the way that alcohol or tobacco are legal. It remains a controlled substance. Cannabis would still sit on the federal drug schedule — just on a lower rung.
Here's what stays exactly the same even if the June 29 hearing goes perfectly:
You still cannot travel across state lines with cannabis. Federal jurisdiction over highways, airports, and borders doesn't change with the schedule number. Taking flower from Michigan to Ohio or through a Detroit Metro Airport security checkpoint would still be a federal issue.
Michigan's state laws and the CRA's rules still govern everything at the local level. Age limits, possession caps, testing requirements, packaging rules, licensing — all of that is Michigan law, not federal law. Rescheduling doesn't touch any of it.
Michigan's state cannabis taxes don't disappear. The federal rescheduling changes federal tax treatment for businesses, not state excise taxes that Michigan charges. If you want to understand how Michigan's wholesale tax affects prices, our post on Michigan's 24% cannabis tax breaks that down.
Cannabis won't suddenly be sold at gas stations or grocery stores. You'll still need a licensed dispensary. Schedule III doesn't create an over-the-counter pathway.
Drug testing at work stays complicated. Employers with federal contracts or federally regulated workplaces can still prohibit cannabis use. Private employers can still set their own policies under Michigan law.
| What Changes | What Doesn't Change |
|---|---|
| Federal tax treatment for businesses (280E gone) | State possession limits and age rules |
| Research barriers (easier to study) | Michigan CRA licensing requirements |
| Banking access (somewhat improved) | State and local cannabis taxes |
| Federal criminal penalty tier (lower) | Cross-state-line or airport rules |
| Medical recognition at federal level | Employer drug testing policies |
The 280E Tax Relief: What It Means for Dispensary Prices #
Section 280E of the federal tax code is the main reason cannabis businesses pay higher effective taxes than almost any other industry — and rescheduling would end that. Understanding 280E is the fastest way to understand why cannabis prices are as high as they are.
Here's how it works. The IRS has a rule — Section 280E — that says you can't deduct normal business expenses if you're trafficking in Schedule I or II drugs. A normal business can subtract rent, payroll, utilities, advertising, and more from its taxable income. A cannabis dispensary cannot. It pays taxes on gross revenue, not net profit, even if the business is barely breaking even.
The result: cannabis businesses pay effective federal tax rates of 40–70%, compared to 20–25% for most other retail businesses. That extra tax burden gets baked into the price on the shelf.
If cannabis moves to Schedule III, 280E no longer applies. Dispensaries and grow operations would be able to deduct normal business expenses like every other small business. That's a massive shift.
Will prices drop immediately? Not overnight. The savings depend on:
- How much each business owes in back taxes vs. going-forward relief
- How competitive the local market is (more competition = more price pressure to pass savings on)
- Whether the IRS provides any retroactive relief for medical operators covered by the April 2026 order
But over time, 280E relief is likely the single biggest financial lever for the industry. It's worth understanding before the June 29 hearing because it's also one of the main reasons the business community is paying close attention to the outcome. The Vicente LLP rescheduling explainer has a thorough breakdown of the business side if you want to go deeper.
Michigan Specifically: How the CRA and State Rules Fit In #
Michigan's Cannabis Regulatory Agency runs the state's cannabis market independently of federal scheduling, so rescheduling doesn't flip any local switches — but the CRA has been watching this process closely and has warned it could create confusion without clear guidance.
In a 2024 public comment filing, the Michigan CRA told the DEA that moving cannabis to Schedule III could have "profound impacts on both the medical and adult-use markets" — and also that it could "wreak havoc" if federal guidance doesn't line up cleanly with state structures.
Here's what Michigan consumers specifically should know:
Your CRA-licensed dispensary isn't going anywhere. Licensing, product testing, seed-to-sale tracking, and retail rules are all under state control. None of that changes because the federal schedule number changed.
Michigan's 10% adult-use excise tax and 6% sales tax stay in place. Federal rescheduling is about federal tax law (280E). State taxes are set by the Michigan Legislature and are separate entirely. For more on how Michigan's wholesale tax structure affects prices, see our post on Michigan's 24% wholesale cannabis tax.
Michigan has both a medical program and an adult-use market. The April 2026 Schedule III order applies to the medical side. Michigan's medical cannabis licenses are state-issued, and those products now have Schedule III status federally. Adult-use remains Schedule I.
Dispensaries in Michigan that serve both medical and adult-use customers could see mixed effects. Medical-side operations might get 280E relief; adult-use operations might not — until the June 29 hearing produces a final broader ruling.
Employment and drug testing rules in Michigan stay the same. Employees at federally regulated workplaces or companies with federal contracts still face the same constraints. State employers can still set their own policies.
The bottom line for Michigan: watch the June 29 hearing, but don't expect anything to change at the counter before a final rule is published and takes effect — which could be months after the hearing concludes.
The Timeline: How We Got Here #
Federal cannabis rescheduling has been in the works since October 2022 — nearly four years of slow, contested, legally complicated process. Here's how the key events stack up.
The Ohio State Drug Enforcement and Policy Center tracks the full federal rescheduling process in detail, and their summary makes clear this has never been a straight line.
| Year | What Happened |
|---|---|
| Oct 2022 | President Biden directed HHS and DOJ to review marijuana's scheduling |
| Aug 29, 2023 | HHS recommended Schedule III in a letter to DEA |
| May 21, 2024 | DOJ/DEA published the formal proposed rule in the Federal Register |
| Late 2024 | First round of DEA administrative hearings began — then stalled |
| Dec 2025 | White House issued executive order to accelerate cannabis and CBD research |
| Apr 22, 2026 | Acting AG Blanche issued a partial Schedule III order |
| Apr 28, 2026 | Order took effect in the Federal Register — medical cannabis now Schedule III |
| Apr 30, 2026 | Prior hearing proceedings formally terminated |
| Jun 29, 2026 | New expedited DEA hearing begins on broader rescheduling |
The Gibson Dunn law firm analysis from April 29, 2026 describes the April move as a "two-step": immediate relief for medical cannabis, with a faster hearing process to settle the broader question. The prior Biden-era hearing proceedings were seen as too slow and too vulnerable to legal challenges, so the new administration restarted under a tighter timeline.
How long will the June 29 hearing take? The Federal Register notice doesn't set a definitive end date. Administrative law hearings like this can take weeks to months depending on how many parties participate and how contested the evidence gets. A final rule could come several months after the hearing concludes.
What Happens After the Hearing? #
After the June 29 hearing concludes, the DEA's administrative law judge will issue a recommendation, and the DEA will then decide whether to publish a final rule. That final rule is what actually changes the law. The hearing is the input, not the output.
Here's the general path after June 29:
- Hearing closes — The ALJ hears testimony from all admitted parties. NORML applied to participate as of late May 2026, along with industry groups and researchers.
- ALJ issues recommended decision — This could take weeks to months after the hearing wraps.
- DEA reviews and issues final rule — The agency doesn't have to follow the ALJ's recommendation but usually does for scientific questions.
- Final rule published in the Federal Register — The effective date is listed in the rule. That's when anything actually changes.
- Potential legal challenges — Any party that participated in the hearing can challenge the final rule in federal court, which can delay implementation.
For Michigan consumers, the realistic best-case scenario looks something like: hearing wraps fall 2026, final rule published late 2026 or early 2027, broader Schedule III takes effect after that. That's not a guarantee — it could go faster or slower.
The other scenario: the hearing surfaces strong objections, the ALJ issues a mixed recommendation, and the process extends. Or opponents challenge the final rule in court.
What to watch for as signals:
- Whether the ALJ sets a tight hearing schedule (signals faster timeline)
- Whether major industry groups or anti-rescheduling parties are admitted (signals contested hearing)
- Any new White House guidance or executive action that accelerates or reverses direction
For now, if you're buying flower at a Michigan dispensary, nothing changes June 29. But if you care about prices, research, and the long-term health of the Michigan market, that hearing is worth keeping an eye on.
What This Means for You Right Now #
If you're a Michigan cannabis consumer, nothing changes at the counter on June 29 — but how this hearing goes will shape the industry you buy from for years. The 280E tax burden is real, and it's one of the reasons prices haven't dropped as fast as many hoped since Michigan went adult-use in 2019. Easier banking means more stable, better-capitalized dispensaries and farms. More research means better product information and smarter dosing guidance down the road.
At Divine Toke, we grow sun-grown organic flower because we believe the plant is best when it's grown clean and cared for properly. Federal policy won't change what we grow or how we grow it — but it will shape how sustainable small operators like us can be over the long run. That's why we're watching June 29 closely.
If you want to go deeper on how Michigan policy affects what you pay and what you can buy, check out these related posts:
- Michigan's 24% wholesale cannabis tax explained — why the state tax structure is its own story
- Schedule III: Medical Only — What Happens Next — a deeper look at the April 2026 medical-only order
- What "Lab Tested" Actually Means in Michigan — how state product rules protect what you buy
Frequently Asked Questions #
Does the DEA hearing mean cannabis is about to become federally legal? #
No — the June 29 hearing does not make cannabis federally legal, and even a successful outcome from the hearing would not legalize it the way alcohol is legal. Rescheduling moves cannabis from Schedule I to Schedule III on the federal drug schedule, but it stays a controlled substance. Per the DEA's own drug scheduling definitions, Schedule III drugs are still federally regulated — they just have different research, tax, and enforcement rules than Schedule I. Full federal legalization would require an act of Congress.
What is Schedule I, and what is Schedule III in plain English? #
Schedule I means the federal government officially says a drug has no accepted medical use and high abuse potential. Schedule III means the drug is recognized as having medical value with lower dependence risk. The DEA's scheduling system runs from I (most restricted) to V (least restricted). Cannabis has sat at Schedule I since 1970 — alongside heroin. Schedule III includes things like ketamine and anabolic steroids. The main practical difference for cannabis: Schedule I businesses can't deduct expenses under the 280E tax rule, and Schedule I substances face steep research barriers.
Did cannabis already move to Schedule III in April 2026? #
Partially yes — but only for two specific categories. On April 28, 2026, the DEA/DOJ order in the Federal Register placed FDA-approved cannabis products and state-licensed medical marijuana in Schedule III. Adult-use and recreational cannabis remained Schedule I. The June 29 hearing is specifically about whether that broader category should also move to Schedule III.
Will rescheduling lower prices at Michigan dispensaries? #
Probably, but gradually and indirectly. The main price driver from rescheduling would be 280E tax relief. As cannabis law analysts at Vicente LLP explain, cannabis businesses currently can't deduct normal operating expenses — rent, payroll, utilities — because of 280E. That can push their effective federal tax rate to 40–70%. Under Schedule III, those deductions return. Over time, healthier margins in a competitive market tend to push retail prices down. But "over time" is the key phrase — don't expect a price drop the morning after a final rule is published.
Can I travel with cannabis if it becomes Schedule III? #
No — rescheduling does not create a legal right to cross state lines or travel through federal spaces with cannabis. Airports, federal highways, and interstate travel involve federal jurisdiction. Cannabis would still be federally controlled under Schedule III, and the TSA and federal law enforcement would still treat it as a controlled substance. Michigan's own rules also limit possession to within the state. This is one of the things that doesn't change with scheduling status alone.
What is Section 280E and how does it affect prices? #
Section 280E is an IRS rule that blocks businesses selling Schedule I or II drugs from deducting normal business expenses on their federal taxes. For a Michigan dispensary, that means no deductions for rent, employee wages, utilities, or marketing. They pay federal tax on gross revenue rather than actual profit — a massive burden that gets passed to customers in the form of higher prices. Spencer Fane's rescheduling analysis explains that Schedule III status would eliminate 280E for qualifying cannabis businesses, potentially reducing effective tax rates by tens of percentage points.
How does the June 29 hearing affect adult-use versus medical cannabis? #
Medical cannabis is already at Schedule III (since April 28, 2026). The June 29 hearing is specifically about adult-use and broader categories still at Schedule I. As the Holland & Knight April 2026 analysis notes, the partial April order drew a clear line: state-licensed medical marijuana is in, adult-use recreational marijuana is not yet in. If the broader hearing succeeds, adult-use would move to Schedule III too. If it stalls or is contested, the split could persist for years.
What does Michigan's CRA say about rescheduling? #
Michigan's Cannabis Regulatory Agency (CRA) filed a public comment in 2024 saying rescheduling could have "profound impacts" on both the medical and adult-use markets — and also warned it could create operational confusion without clear guidance. The CRA's formal comment to the DEA highlighted concerns about how federal and state rules would interact, especially around licensing and product categories. The CRA continues to govern Michigan's dispensaries and growers regardless of federal scheduling.
How long will the June 29 hearing take? #
The DEA has not set a fixed end date, and administrative law hearings like this can take weeks to months depending on how many parties participate and how contested the record gets. The Federal Register hearing notice describes this as an "expedited" process, which signals the government wants to move faster than the prior round. Still, hearings of this significance often stretch longer than expected, especially if major industry or advocacy groups are admitted as parties.
Will rescheduling change what products are sold at dispensaries? #
Not directly. Product types, testing requirements, and what dispensaries can carry are all governed by Michigan's CRA, not by federal scheduling. Rescheduling would not suddenly allow edibles, concentrates, or anything currently prohibited in Michigan. It might, over time, make it easier for researchers to develop new cannabis-based medicines — but that's a multi-year pipeline, not an overnight dispensary menu change.
What is the difference between rescheduling and legalization? #
Rescheduling moves cannabis to a less restricted federal category but keeps it controlled. Legalization would remove it from federal drug schedules entirely — like alcohol or tobacco. According to the Drug Policy Alliance's 2026 explainer, the rescheduling process does not give consumers the kind of broad federal rights they would have with full legalization. Cannabis advocates like NORML support both rescheduling as a near-term step and full descheduling as a longer-term goal. These are separate legal processes.
When could broader rescheduling actually take effect? #
If the June 29 hearing goes smoothly and the DEA acts quickly, a final rule on broader rescheduling could realistically be published in late 2026 or early 2027 — but it's not guaranteed. Legal challenges from any party admitted to the hearing can delay a final rule. The Ohio State Drug Enforcement and Policy Center's ongoing tracker is one of the best places to follow the process in real time. For context, the prior round of rescheduling efforts took about two years from proposal to stalling — this new expedited track aims to be faster, but "faster" in federal rulemaking still means months, not weeks.
